BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 237 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $235,631 | -4.4% | 38,128 | -21.4% | 0.00% | 0.0% |
Q1 2024 | $246,395 | -7.5% | 48,503 | +9.1% | 0.00% | 0.0% |
Q4 2023 | $266,327 | +1.6% | 44,462 | +20.1% | 0.00% | 0.0% |
Q3 2023 | $262,046 | +0.9% | 37,012 | +0.4% | 0.00% | 0.0% |
Q2 2023 | $259,621 | -10.8% | 36,878 | +5.7% | 0.00% | 0.0% |
Q1 2023 | $291,041 | -35.5% | 34,897 | -11.2% | 0.00% | -50.0% |
Q4 2022 | $450,992 | -0.9% | 39,285 | +8.9% | 0.00% | 0.0% |
Q3 2022 | $455,000 | +21.7% | 36,083 | +2.2% | 0.00% | +100.0% |
Q2 2022 | $374,000 | -56.5% | 35,293 | -33.2% | 0.00% | -50.0% |
Q1 2022 | $860,000 | -3.8% | 52,869 | -18.1% | 0.00% | 0.0% |
Q4 2021 | $894,000 | +1.9% | 64,573 | +5.9% | 0.00% | 0.0% |
Q3 2021 | $877,000 | -28.9% | 60,998 | -21.9% | 0.00% | -50.0% |
Q2 2021 | $1,234,000 | +69.3% | 78,054 | +8.9% | 0.00% | +100.0% |
Q1 2021 | $729,000 | +47.3% | 71,674 | +8.0% | 0.00% | 0.0% |
Q4 2020 | $495,000 | +187.8% | 66,380 | +32.5% | 0.00% | +100.0% |
Q3 2020 | $172,000 | -25.9% | 50,107 | +3.1% | 0.00% | 0.0% |
Q2 2020 | $232,000 | +286.7% | 48,619 | +61.0% | 0.00% | – |
Q1 2020 | $60,000 | -67.4% | 30,205 | -43.4% | 0.00% | -100.0% |
Q4 2019 | $184,000 | +50.8% | 53,393 | +25.8% | 0.00% | 0.0% |
Q3 2019 | $122,000 | -26.5% | 42,441 | -3.0% | 0.00% | 0.0% |
Q2 2019 | $166,000 | -58.5% | 43,755 | -10.9% | 0.00% | -50.0% |
Q1 2019 | $400,000 | +1.8% | 49,111 | +0.9% | 0.00% | -33.3% |
Q4 2018 | $393,000 | -11.1% | 48,660 | -16.0% | 0.00% | 0.0% |
Q3 2018 | $442,000 | +41.7% | 57,953 | +6.3% | 0.00% | +50.0% |
Q2 2018 | $312,000 | +12.6% | 54,502 | -6.1% | 0.00% | 0.0% |
Q1 2018 | $277,000 | -16.6% | 58,035 | -14.1% | 0.00% | 0.0% |
Q4 2017 | $332,000 | +24.8% | 67,561 | +33.0% | 0.00% | 0.0% |
Q3 2017 | $266,000 | -1.1% | 50,807 | +5.1% | 0.00% | -33.3% |
Q2 2017 | $269,000 | -33.3% | 48,354 | +0.9% | 0.00% | -25.0% |
Q1 2017 | $403,000 | +5.2% | 47,927 | -20.8% | 0.00% | 0.0% |
Q4 2016 | $383,000 | +61.6% | 60,527 | +12.6% | 0.00% | +33.3% |
Q3 2016 | $237,000 | +30.9% | 53,737 | -15.8% | 0.00% | +50.0% |
Q2 2016 | $181,000 | +1.7% | 63,843 | +1.4% | 0.00% | 0.0% |
Q1 2016 | $178,000 | -75.2% | 62,967 | -9.4% | 0.00% | -77.8% |
Q4 2015 | $718,000 | +0.3% | 69,532 | +10.8% | 0.01% | -10.0% |
Q3 2015 | $716,000 | -28.5% | 62,777 | -6.4% | 0.01% | -28.6% |
Q2 2015 | $1,002,000 | +55.3% | 67,096 | -6.1% | 0.01% | +75.0% |
Q1 2015 | $645,000 | -15.2% | 71,441 | +14.2% | 0.01% | -11.1% |
Q4 2014 | $761,000 | +20.2% | 62,577 | -3.3% | 0.01% | +12.5% |
Q3 2014 | $633,000 | -35.2% | 64,742 | -15.5% | 0.01% | -38.5% |
Q2 2014 | $977,000 | +104.0% | 76,608 | +69.4% | 0.01% | +116.7% |
Q1 2014 | $479,000 | +143.1% | 45,235 | +74.7% | 0.01% | +100.0% |
Q4 2013 | $197,000 | +264.8% | 25,886 | -25.2% | 0.00% | +200.0% |
Q2 2013 | $54,000 | – | 34,599 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |